Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) recently announced the appointment of Dr. Pushkal Garg as Executive Vice President and Chief Research and Development Officer to accelerate its R&D efforts.

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

RBC Capital maintained its Outperform rating and $330.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) following positive survey data on its recently expanded Amvuttra treatment.The firm ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference ... Chief Medical Officer at Alnylam. “AMVUTTRA is supported by a well-established efficacy and safety profile, ...

Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy. − First and Only RNAi Therapeutic Approved by the European ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

Alnylam-Aktie vor starkem Quartal - Amvuttra-Einführung an Fahrt gewinnt: 13.06. Alnylam stock poised for strong quarter as Amvuttra launch gains traction: Firmen im Artikel. 5-Tage-Chart ...

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy Jun. 09, 2025 6:00 AM ET Alnylam Pharmaceuticals, Inc. (ALNY) ...

The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.